The condemnations keep coming after five diabetes experts were escorted out of an ADA meeting for handing out copies of an editorial criticizing federal research cuts.
Vetenskapsnyheter
Federal health regulators on Tuesday signed off on the first new sunscreen ingredient for the U.S. market in more than 25 years.
The Trump administration has warned more than 500 hospitals that they are failing to provide the public with basic pricing information.
AstraZeneca's GLP-1 pill, GSK's $10.6B cancer startup acquisition, and more biotech news from The Readout
The NIH has appointed researcher John Powers III to lead its infectious disease institute on an acting basis, after weeks of being in leadership limbo.
GSK agreed to buy Nuvalent, a cancer drug developer, in a deal worth $10.6 billion, as the company continues its expansion in oncology
In this edition of STAT Health Tech: Dexcom's CGM trial, udpates from Apple's annual developers' conference, and wearables.
In a report published on the first anniversary of the Bethesda Declaration, 71 staffers write that they feel NIH leadership “largely ignored" their concerns
A suppressed federal alcohol report, an "inevitable development" for wearables data, and more health news from Morning Rounds
Is it “health care” or “healthcare”? STAT readers had strong feelings.
Hospital execs say they're working to mitigate the impacts of the looming cuts.
Wearables generate a lot of health data, but it exists outside the clinic for the most part. New moves from Oura and Whoop may change that.
As the world deals with an outbreak of Ebola that has no known cure, Susan Reichle, who last year co-founded Aid Transition Alliance to support former USAID professionals, discusses the…
“Innovations like xenotransplantation would never have reached clinical trials without animal experimentation,” writes transplant surgeon Joshua Mezrich.
GSK is buying Nuvalent, the maker of targeted cancer drugs, for $10.6 billion, a sizable addition to the latest run of biopharma acquisitions.
A government-commissioned study had been meant to inform new dietary guidelines, and found risks associated with even light drinking.
Health workers at the epicenter of Congo's Ebola outbreak are laboring with little pay or rest.
AstraZeneca’s GLP-1 pill showed promise in mid-stage obesity and diabetes studies, but it may still be too early to determine how it stacks up against other oral treatments.
The biggest U.S. health insurer is changing how it pays for lactation counseling, and it could cut payment for many providers.
Revolution and Tango yield promising cancer results, Incyte buys bleeding disorder drug, and more biotech news
Lilly disclosed new data that provide more details on the safety and tolerability of its next-generation obesity drug retatrutide
Johnson & Johnson said it will purchase the startup Firefly Bio for $1 billion in an effort to expand its work in the suddenly buzzy field of KRAS inhibitors.
Why "Schedule F" matters, the Ebola outbreak response, and more health news from Morning Rounds
A combination of pancreatic cancer drugs from Tango Therapeutics and Revolution Medicines led to a strong response rate in an early-stage trial.
“We do not lack cures. We lack the infrastructure to pay for and deliver them,” writes William Padula.